Fenofibrate and risk of minor amputations in diabetes

The Lancet

Volumn 373, Issue 9677, 2009, Pages 1740-1741

  Fazio, Sergio ^a   Linton, MacRae F ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FENOFIBRATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; STATIN;

ARTICLE; ATHEROMA; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL PROTOCOL; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE COURSE; DYSLIPIDEMIA; FOOT AMPUTATION; HEART INFARCTION; HUMAN; LIFESTYLE; MICROALBUMINURIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVASCULARIZATION; SKIN ULCER; VASCULAR ENDOTHELIUM; WOUND HEALING;

EID: 65649128201     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)60959-4     Document Type: Note

References (15)

1. Rajamani K., Colman P.G., Li L.P., et al., on behalf of the FIELD study investigators. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 373 (2009) 1780-1788
2. The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
3. FIELD study investigators. The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]. Cardiovasc Diabetol 3 (2004) 9
4. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
5. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371 (2008) 117-125
6. Douglas K., O'Malley P.G., and Jackson J.L. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med 145 (2006) 117-124
7. Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20 536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg 45 (2007) 645-654
8. Keech A.C., Mitchell P., Summanen P.A., et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 370 (2007) 1687-1697
9. Lincoln N.B., Radford K.A., Game F.L., and Jeffcoate W.J. Education for secondary prevention of foot ulcers in people with diabetes: a randomised controlled trial. Diabetologia 51 (2008) 1954-1961
10. Van Damme H., and Limet R. Amputation in diabetic patients. Clin Podiatr Med Surg 24 (2007) 569-582
11. Feingold K.R. The importance of lipids in cutaneous function. J Lipid Res 48 (2007) 2529-2530
12. Komuves L.G., Hanley K., Lefebvre A.M., et al. Stimulation of PPARalpha promotes epidermal keratinocyte differentiation in vivo. J Invest Dermatol 115 (2000) 353-360
13. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361 (2003) 2005-2016
14. Holman R.R., Paul S.K., Bethel M.A., Neil H.A., and Matthews D.R. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 359 (2008) 1565-1576
15. Belch J., MacCuish A., Campbell I., et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 337 (2008) a1840